- Home
- CII vs EMBC Comparison
CII vs EMBC Comparison
Compare CII & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CII
- EMBC
- Stock Information
- Founded
- CII 2004
- EMBC 1924
- Country
- CII United States
- EMBC United States
- Employees
- CII N/A
- EMBC N/A
- Industry
- CII Investment Bankers/Brokers/Service
- EMBC Medical/Dental Instruments
- Sector
- CII Finance
- EMBC Health Care
- Exchange
- CII Nasdaq
- EMBC Nasdaq
- Market Cap
- CII 870.4M
- EMBC 838.7M
- IPO Year
- CII N/A
- EMBC N/A
- Fundamental
- Price
- CII $23.22
- EMBC $13.83
- Analyst Decision
- CII
- EMBC Buy
- Analyst Count
- CII 0
- EMBC 2
- Target Price
- CII N/A
- EMBC $18.50
- AVG Volume (30 Days)
- CII 78.8K
- EMBC 514.0K
- Earning Date
- CII 01-01-0001
- EMBC 11-25-2025
- Dividend Yield
- CII 6.17%
- EMBC 4.32%
- EPS Growth
- CII N/A
- EMBC 18.26
- EPS
- CII N/A
- EMBC 1.42
- Revenue
- CII N/A
- EMBC $1,102,500,000.00
- Revenue This Year
- CII N/A
- EMBC N/A
- Revenue Next Year
- CII N/A
- EMBC N/A
- P/E Ratio
- CII N/A
- EMBC $9.77
- Revenue Growth
- CII N/A
- EMBC N/A
- 52 Week Low
- CII $16.76
- EMBC $9.20
- 52 Week High
- CII $19.81
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- CII 67.79
- EMBC 44.40
- Support Level
- CII $22.44
- EMBC $13.78
- Resistance Level
- CII $23.39
- EMBC $14.78
- Average True Range (ATR)
- CII 0.22
- EMBC 0.53
- MACD
- CII 0.02
- EMBC -0.14
- Stochastic Oscillator
- CII 85.29
- EMBC 14.97
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.